KFU. Card publication. Periostin as a Biomarker of Allergic Inflammation in Atopic Bronchial Asthma and Allergic Rhinitis (a Pilot Study)

KAZAN
FEDERAL UNIVERSITY

- RUS
- 中文
- ES

PERIOSTIN AS A BIOMARKER OF ALLERGIC INFLAMMATION IN ATOPIC BRONCHIAL ASTHMA AND ALLERGIC RHINITIS (A PILOT STUDY)

Form of presentation

Articles in Russian journals and collections

Year of publication

2020

��

��

Authors, employees of KFU

Kubysheva Nailya Iskhakovna, author

Other authors

Eliseeva Tatyana , author

Frolov Pavel , author

Krasilnikova Svetlana , author

Ovsyannikov Dmitry , author

Terentyeva Anna , author

Tush Elena , author

Bibliographic description in the original language

Krasilnikova, S. V., Tush, E. V., Frolov, P. A., Ovsyannikov, D. Y., Terentyeva, A. B., Kubysheva, N. I., & Eliseeva, T. I. (2020). Periostin as a Biomarker of Allergic Inflammation in Atopic Bronchial Asthma and Allergic Rhinitis (a Pilot Study). Sovremennye tekhnologii v medicine, 12(5 (eng)).

Annotation

The involvement of periostin in Th2-dependent allergic inflammation has been documented. However, the significance of periostin as a biomarker of local allergic inflammation in the nasal mucosa (NM) of patients with atopic bronchial asthma (BA) and allergic rhinitis (AR) is yet to be determined. The aim of the study was to determine the presence of periostin and evaluate its role as a non-invasive marker of allergic inflammation in the nasal secretions of children with atopic BA and AR. Materials and Methods. In 43 patients aged 4–17 years with atopic BA and AR, the NM was examined using nasal video-endoscopy and (if indicated) computed tomography; the amount of periostin in the nasal secretion was determined by the enzyme immunoassay. Results. Exacerbation ofAR was accompanied by a statistically significant increase in the level of periostin in the nasal secretion: up to 0.84 [0.06; 48.79] ng/mg, whereas in remission, that was 0.13 [0.00; 0.36] ng/mg; p=0.04. This value increased progressively as the severity of AR increased from 0.16 [0.00; 0.36] ng/mg in the mild course to 0.20 [0.00; 9.03] ng/mg in AR of moderate severity, and to 10.70 [0.56; 769.20] ng/mg in most severe cases; p=0.048. Hypertrophy or polyposis of the nasal and/or paranasal mucosa was detected in 34.9% (15/43) of the examined patients. The concentration of periostin in the nasal secretion was lower in children without NM hypertrophy: 0.18 [0.001; 4.30] ng/mg vs 0.78 [0.13; 162.10] ng/mg in patients with NM hypertrophy; the differences were close to statistically significant: p=0.051. The level of nasal periostin depended on the clinical form of hypertrophy in the sinonasal mucosa, reaching 0.17 [0.00; 0.32] ng/mg in children with polyposis hyperplasia of NM and 21.6 [10.70; 1516.80] ng/mg — with hypertrophy of the NM in the medial surface of the concha; p=0.02. Conclusion. Exacerbation and increased severity of AR in patients with atopic BA are accompanied by an increased level of periostin in the nasal secretion. This allows us to consider the level of nasal periostin as a biomarker of local allergic inflammation in the NM of patients with atopic BA combined with AR. Hypertrophic changes in the sinonasal mucosa are generally accompanied by an increased level of nasal periostin; specifically, this level significantly depends on the clinical form of mucous membrane hypertrophy and requires additional studies.

Keywords

periostin, bronchial asthma, allergic rhinitis, chronic rhinosinusitis with polyps

The name of the journal

SOVREMENNYE TEHNOLOGII V MEDICINE

URL

http://www.stm-journal.ru/ru/numbers/2020/5/1666

Please use this ID to quote from or refer to the card

https://repository.kpfu.ru/eng/?p_id=244281&p_lang=2

Resource files

File name	Size (MB)	Format
F_Periostin_as_a_Biomarker_of_Allergic_Inflammation_in_Atopic_Bronchial_Asthma_and_Allergic_Rhinitis.pdf	0,47	pdf	show / download

Full metadata record

Field DC	Value	Language
dc.contributor.author	Kubysheva Nailya Iskhakovna	ru_RU
dc.contributor.author	Eliseeva Tatyana	ru_RU
dc.contributor.author	Frolov Pavel	ru_RU
dc.contributor.author	Krasilnikova Svetlana	ru_RU
dc.contributor.author	Ovsyannikov Dmitry	ru_RU
dc.contributor.author	Terentyeva Anna	ru_RU
dc.contributor.author	Tush Elena	ru_RU
dc.date.accessioned	2020-01-01T00:00:00Z	ru_RU
dc.date.available	2020-01-01T00:00:00Z	ru_RU
dc.date.issued	2020	ru_RU
dc.identifier.citation	Krasilnikova, S. V., Tush, E. V., Frolov, P. A., Ovsyannikov, D. Y., Terentyeva, A. B., Kubysheva, N. I., & Eliseeva, T. I. (2020). Periostin as a Biomarker of Allergic Inflammation in Atopic Bronchial Asthma and Allergic Rhinitis (a Pilot Study). �� , 12(5 (eng)).	ru_RU
dc.identifier.uri	https://repository.kpfu.ru/eng/?p_id=244281&p_lang=2	ru_RU
dc.description.abstract	SOVREMENNYE TEHNOLOGII V MEDICINE	ru_RU
dc.description.abstract	The involvement of periostin in Th2-dependent allergic inflammation has been documented. However, the significance of periostin as a biomarker of local allergic inflammation in the nasal mucosa (NM) of patients with atopic bronchial asthma (BA) and allergic rhinitis (AR) is yet to be determined. The aim of the study was to determine the presence of periostin and evaluate its role as a non-invasive marker of allergic inflammation in the nasal secretions of children with atopic BA and AR. Materials and Methods. In 43 patients aged 4–17 years with atopic BA and AR, the NM was examined using nasal video-endoscopy and (if indicated) computed tomography; the amount of periostin in the nasal secretion was determined by the enzyme immunoassay. Results. Exacerbation ofAR was accompanied by a statistically significant increase in the level of periostin in the nasal secretion: up to 0.84 [0.06; 48.79] ng/mg, whereas in remission, that was 0.13 [0.00; 0.36] ng/mg; p=0.04. This value increased progressively as the severity of AR increased from 0.16 [0.00; 0.36] ng/mg in the mild course to 0.20 [0.00; 9.03] ng/mg in AR of moderate severity, and to 10.70 [0.56; 769.20] ng/mg in most severe cases; p=0.048. Hypertrophy or polyposis of the nasal and/or paranasal mucosa was detected in 34.9% (15/43) of the examined patients. The concentration of periostin in the nasal secretion was lower in children without NM hypertrophy: 0.18 [0.001; 4.30] ng/mg vs 0.78 [0.13; 162.10] ng/mg in patients with NM hypertrophy; the differences were close to statistically significant: p=0.051. The level of nasal periostin depended on the clinical form of hypertrophy in the sinonasal mucosa, reaching 0.17 [0.00; 0.32] ng/mg in children with polyposis hyperplasia of NM and 21.6 [10.70; 1516.80] ng/mg — with hypertrophy of the NM in the medial surface of the concha; p=0.02. Conclusion. Exacerbation and increased severity of AR in patients with atopic BA are accompanied by an increased level of periostin in the nasal secretion. This allows us to consider the level of nasal periostin as a biomarker of local allergic inflammation in the NM of patients with atopic BA combined with AR. Hypertrophic changes in the sinonasal mucosa are generally accompanied by an increased level of nasal periostin; specifically, this level significantly depends on the clinical form of mucous membrane hypertrophy and requires additional studies.	ru_RU
dc.language.iso	ru	ru_RU
dc.subject	periostin	ru_RU
dc.subject	bronchial asthma	ru_RU
dc.subject	allergic rhinitis	ru_RU
dc.subject	chronic rhinosinusitis with polyps	ru_RU
dc.title	Periostin as a Biomarker of Allergic Inflammation in Atopic Bronchial Asthma and Allergic Rhinitis (a Pilot Study)	ru_RU
dc.type	Articles in Russian journals and collections	ru_RU